CSPG4 and neoplasm: In melanoma models, CAR-NKT cells targeting chondroitin sulfate proteoglycan 4 (CSPG4) demonstrated superior tumour elimination compared to CAR-T cells, with faster expansion rates and enhanced infiltration into TME [275]​.